This study aims to observe the effects of the availability of plerixafor on the time and effort associated with autologous peripheral blood stem cell collection.

This non interventional study will consist of two parts:

I. Retrospective study:

A medical record review will be conducted covering 200 patients file undergoing peripheral blood stem cell mobilization in some European centers.

II. Prospective study :Time/Motion evaluation of actual apheresis - 20 events each center The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.

Inclusion Criteria:

Patients must satisfy the following for the part 1

• Oncology patients diagnosed with Non-Hodgkin lymphoma who are candidates for autologous hematopoietic stem cell transplantation (HSCT)
• A patient that fails to achieve a target CD34+>20 cells/µl, before or on the first day of apheresis
• Age > 18 years

Exclusion Criteria for the part 1

Patients with:

• Age < 18 years;
• Primary diagnosis other than Non-Hodgkin lymphoma
• Undergone prior autologous hematopoietic stem cell transplantation (HSCT)

The study will consist of two parts:

I. Retrospective study:

A medical record review will be conducted covering 200 patients file undergoing peripheral blood stem cell mobilization in different European centers. Patients will be selected from each of centers, evenly divided between two eras: 1) prior to approval of plerixafor= Pre-P era (July 2009); and 2) after approval of plerixafor= P era .

II. Prospective study :Time/Motion evaluation of actual apheresis - 20 events each center